Brief: Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49
11/10/2026 22:03
BRIEF-Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49 Oct 11 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA - EFZIMFOTASE ALFA SHOWS IMPROVEMENT IN PRIMARY AND KEY SECONDARY ENDPOINTS AT WEEK 25 AND WEEK 49
Source text: ID:nWkr4j8yfc
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines